ASCO 2019: 40-50 percent response rate for brigatinib after other next-gen ALK inhibitors
IMAGE: D. Ross Camidge, MD, PhD and the ATOMIC consortium show that brigatinib remains effective even after first-line therapy with another next-generation ALK inhibitor. view more Credit: University of Colorado Cancer Center Crizotinib was the first drug licensed to treat ALK-positive non-small cell lung cancer (ALK+ NSCLC). Since then, a range of next-generation ALK-inhibitors including ceritinib,…